Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $35.71

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $35.71.

A number of brokerages recently weighed in on DAWN. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. JPMorgan Chase & Co. lowered their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $13.84 on Thursday. The company has a market cap of $1.40 billion, a PE ratio of -13.44 and a beta of -1.51. The stock has a fifty day moving average price of $14.32 and a 200 day moving average price of $14.13. Day One Biopharmaceuticals has a 1-year low of $11.51 and a 1-year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the business posted ($0.54) EPS. Analysts anticipate that Day One Biopharmaceuticals will post -0.88 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Samuel C. Blackman sold 11,245 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $16.03, for a total value of $180,257.35. Following the transaction, the insider now directly owns 1,085,790 shares in the company, valued at $17,405,213.70. This trade represents a 1.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 51,745 shares of company stock valued at $775,867 in the last 90 days. 8.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently bought and sold shares of DAWN. Franklin Resources Inc. raised its stake in shares of Day One Biopharmaceuticals by 2.3% during the third quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company’s stock valued at $55,336,000 after purchasing an additional 87,262 shares during the period. Geode Capital Management LLC increased its stake in Day One Biopharmaceuticals by 10.5% during the third quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock valued at $19,961,000 after purchasing an additional 136,458 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Day One Biopharmaceuticals in the third quarter valued at $9,607,000. XTX Topco Ltd bought a new position in shares of Day One Biopharmaceuticals in the third quarter worth $178,000. Finally, Wellington Management Group LLP raised its position in shares of Day One Biopharmaceuticals by 142.1% during the 3rd quarter. Wellington Management Group LLP now owns 721,581 shares of the company’s stock worth $10,052,000 after buying an additional 423,543 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.